Related Experiment Videos

Pleomorphic rhabdomyosarcoma in adults: immunohistochemistry as a tool for its diagnosis

Human Pathology
|March 1, 1987
PubMed

Insights

Pleomorphic rhabdomyosarcoma is rare in adults over 30. Immunohistochemistry reclassified most historical cases as malignant fibrous histiocytoma (MFH) or leiomyosarcoma, highlighting diagnostic challenges.

Area of Science:

  • Oncology
  • Pathology
  • Immunohistochemistry

Background:

  • Pleomorphic rhabdomyosarcoma was frequently diagnosed in adults over 30 in the mid-20th century.
  • The acceptance of malignant fibrous histiocytoma (MFH) as a distinct entity reduced the incidence of pleomorphic rhabdomyosarcoma diagnoses.

Purpose of the Study:

  • To re-evaluate historical diagnoses of pleomorphic rhabdomyosarcoma in adults using immunohistochemistry.
  • To clarify the diagnostic accuracy of histology and electron microscopy for pleomorphic sarcomas.

Main Methods:

  • Re-examination of 21 historical pleomorphic rhabdomyosarcoma cases using immunohistochemistry.
  • Utilized antibodies against vimentin, desmin, creatine kinase subunit M, skeletal muscle actin/myosin, and myoglobin.
  • Employed the avidin-biotin-peroxidase complex technique.

Main Results:

  • Immunohistochemistry revealed that most adult pleomorphic rhabdomyosarcomas are rare, with many reclassified as MFH or leiomyosarcoma.
  • Routine histology and electron microscopy led to misdiagnosis of some pleomorphic sarcomas as MFH or liposarcoma.
  • One case was reclassified as pleomorphic rhabdomyosarcoma, and others as pleomorphic leiomyosarcoma.

Conclusions:

  • Immunohistochemistry is crucial for accurate diagnosis of pleomorphic sarcomas in adults.
  • Historical diagnoses of pleomorphic rhabdomyosarcoma in adults require re-evaluation.
  • Distinguishing between pleomorphic sarcomas like rhabdomyosarcoma, MFH, and leiomyosarcoma benefits from advanced techniques.

Related Concept Videos